Die HAEMATO AG ist ein Spezial-Pharmazeutika Unternehmen.

HAEMATO PHARM GmbH

HAEMATO PHARM GmbH specializes in the manufacture and sale of generics and EU original medicines. With its product portfolio, the company focuses on five major therapeutic areas: HIV / AIDS, Neurology, Oncology, Rheumatology and Urology.

HAEMATO MED GmbH

HAEMATO MED GmbH is an innovative healthcare company specializing in the development and commercialization of pharmaceutical, medical and medical devices for aesthetic surgery and cosmetic dermatology.

HAEMATO AG

HAEMATO AG is a publicly traded pharmaceutical company focusing on the growth markets of high-end specialty pharmaceuticals in the indication areas of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the in-house development of innovative medical devices for the beauty market was started. HAEMATO AG assumes that first products will hit the market in the coming year, which has already created the basis for further growth and additional income.

News

We inform you about the current business development of HAEMATO AG and about our investor relations activities.

HAEMATO AG Corporate News: Preliminary IFRS results 2019

by Haemato AG | Mar 25, 2020 | Investor News

HAEMATO AG Corporate News: HAEMATO AG was able to achieve sales of 197.8 mEUR and an EBITDA of 1.9 mEUR for the fiscal year 2019 according to preliminary IFRS financial statements. HAEMATO AG, Berlin (ISIN: DE0006190705), achieved consolidated sales of 197.8 mEUR...

IFRS Third-Quarter 2019 Results

by Haemato AG | Nov 25, 2019 | Allgemein

In the third quarter of 2019 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated revenues of EUR 47.8 million. In the considered period from January to Sep-tember 2019 the sales totaled EUR 141.8 million (previous year: EUR 212.8 million). The EBITDA...

Interim Report 2019

by Haemato AG | Aug 26, 2019 | Allgemein

In the first half of 2019, HAEMATO AG achieved EBITDA of EUR 1.69 million. Sales amounted to EUR 94.0 million. In the first six months of the financial year 2019, HAEMATO AG, Berlin (ISIN: DE0006190705), achieved an IFRS consolidated revenue of EUR 94.0 million...

Click here for more news

Publications

Get an overview of the current status and development of HAEMATO AG. Here you will find information on the current status of the Group and on developments in recent years.

Read the Reports